Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

BTK

Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development.

  • Tirabrutinib hydrochloride
    T123111439901-97-9
    Tirabrutinib hydrochloride (GS-4059 (hydrochloride)) is a selective and novelBTK with IC50 2.2 nm inhibitor.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Sunvozertinib
    T641242370013-12-8
    Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor and has inhibitory effects on EGFR, Her2 and mutant epidermal growth factor. Sunvozertinib showed inhibition of EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutation, and Her2 exon 20 YVMA and EGFR WT A431. IC50 were 20.4, 20.4, 1.1, 7.5 and 80.4 nM, respectively.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Ibrutinib
    T1835936563-96-1
    Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
    • $36
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • IBT6A
    T106251022150-12-4
    IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
    • $42
    In Stock
    Size
    QTY
  • CP-547632
    T10870L252003-65-9In house
    CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective, with higher selectivity for VEGFR2 and bFGF than for EGFR, PDGFRβ and related tyrosine kinases (TKs). PDGFRβ and related tyrosine kinases (TKs) CP-547632 has antitumour activity.
    • $30
    In Stock
    Size
    QTY
  • Edralbrutinib
    T632721858206-58-2In house
    Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood and lymphatic system disorders.Edralbrutinib is used in the study of membranous glomerulonephritis and optic neuromyelitis optica.
    • $350
    In Stock
    Size
    QTY
  • BTK-IN-16
    T605422883232-92-4
    BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.
    • $350
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Larotinib
    T733341438072-11-7
    Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
    • $74
    In Stock
    Size
    QTY
  • Acalabrutinib enantiomer
    T678811952316-43-6
    Acalabrutinib enantiomer (R-Acalabrutinib) is a chemical compound that belongs to the class of Bruton’s tyrosine kinase (BTK) inhibitors. Acarabitinib enantiomers can be used in the study of cancer, autoimmune diseases and chronic inflammation.
    • $117
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • N-piperidine Ibrutinib
    T9408330785-90-5
    N-piperidine Ibrutinib is a potent BTK inhibitor with IC50s of 51.0 for WT BTK and 30.7 nM for C481S BTK respectively. N-piperidine Ibrutinib can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620. SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM.
    • $148
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • XMU-MP-2
    T699802031152-10-8In house
    XMU-MP-2 is a potent and selective protease inhibitor with anticancer activity that inhibits the growth of oncogenic BRK-driven tumors in a mouse xenograft model.
    • $195
    In Stock
    Size
    QTY
  • QL-X-138 HCl
    T38960L In house
    QL-X-138 HCl is a novel selective and highly potent BTK/MNK dual-kinase inhibitor with anticancer activity that binds covalently to BTK and noncovalently to MNK. QL-X-138 HCl inhibited BTK, MNK1, and MNK2 kinases. QL-X-138 HCl has anti-dengue virus 2 activity and shows anti-proliferative activity in acute myeloid leukemia cells. QL-X-138 HCl can be used to study lymphoma and leukemia.
    • $195
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BTK inhibitor 1
    T353302230724-66-8In house
    BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.
    • $97
    In Stock
    Size
    QTY
  • JAK3/BTK-IN-1
    T98142674036-91-8In house
    JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases. JAK3/ BTk-in-1 simultaneously inhibited the BTK/JAK3 signaling pathway, showing a synergistic effect. JAK3/ BTK-in-1 is a potential compound for the treatment of immune-related diseases, such as autoimmune diseases, certain types of cancer (including lymphoma and leukemia), and other diseases that may be characterized by an unbalanced immune response.
    • $1,330
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • ACP-5862
    T102402230757-47-6In house
    ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective BTK inhibitor (IC50: 3 nM; EC50: 8 nM).
    • $1,520
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • JAK3/BTK-IN-2
    T98132674036-93-0In house
    JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor. JAK3/ BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3/ BTk-in-2 simultaneously inhibits the BTK/JAK3 signaling pathway, showing a synergistic effect. JAK3/ BTk-in-2 has the potential to treat diseases associated with abnormal JAK3 and BTK activity.
    • $1,330
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • QL-X-138
    T389601469988-63-3In house
    QL-X-138 is a potent and selective BTK and MNK dual kinase inhibitor that binds covalently to BTK and non-covalently to MNK.The IC 50 s of QL-X-138 against BTK, MNK1 and MNK2 kinases are 9.4 nM, 107.4 nM and 26 nM, respectively.The IC 50 s of QL-X-138 against Dengue 2 is 3.5 μM.QL-X-138 is used in the study of B-cell malignancies. QL-X-138 inhibits dengue virus 2 with an IC 50 of 3.5 μM. QL-X-138 can be used in the study of B-cell malignant tumors.
    • $193
    In Stock
    Size
    QTY
  • RN486
    T19761242156-23-5
    RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).
    • $77
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Saracatinib
    T6078379231-04-6
    Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
    • $59
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • BIIB068
    T91921798787-27-5
    BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.
    • $66
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • LFM-A13
    T6217244240-24-2
    LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.
    • $31
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • BTK inhibitor 17
    T97061858206-76-4
    BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.
    • $143
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BLK degrader 1
    T77518
    BLK degrader 1 is a selective B lymphoid tyrosine kinase (BLK) degrader with anticancer activity and can be used for cancer research.
    • $133
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BTK IN-1
    TQ02301270014-40-8
    BTK IN-1 (SNS062 analog) (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
    • $32
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • JDB175
    T820102635328-79-7
    JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier. It exhibits potent activity against central nervous system lymphoma in a mouse model, with no apparent toxicity. JDB175 effectively suppresses human lymphoma cell proliferation by inhibiting the BTK signaling pathway, induces cell cycle arrest, and promotes apoptosis[1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • MT-802
    T161572231744-29-7
    MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).
    • $147
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • (Rac)-IBT6A
    T106261412418-47-3
    (Rac)-IBT6A is the racemate of IBT6A. IBT6A is an impurity of ibrutinib and can be used in the synthesis of IBT6A ibrutinib dimers and IBT6A adducts. 3',4'-Dimerization of ibrutinib and ibrutinib dimers.
    • $49
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AS-1763
    T397072227211-00-7
    AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.
    • $233
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • DBt-10
    T79890
    DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • PCI-33380
    T164411022899-36-0
    PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
    • $996
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • PROTAC BTK Degrader-6
    T787822767204-39-5
    PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression of pro-inflammatory cytokines, such as IL-1β and IL-6 [1].
    • Inquiry Price
    Size
    QTY
  • BTK-IN-25
    T791132562351-92-0
    BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].
    • Inquiry Price
    Size
    QTY
  • CGI-1746
    T2472910232-84-7
    CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
    • $34
    In Stock
    Size
    QTY
  • Orelabrutinib
    T123171655504-04-3
    Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
    • $83
    In Stock
    Size
    QTY
  • Syk Inhibitor II dihydrochloride
    T4391227449-73-2
    Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chains and mediates downstream signaling related to platelet function and inflammation. Syk inhibit
    • $132
    In Stock
    Size
    QTY
  • PCI 29732
    T4337330786-25-9
    PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
    • $34
    In Stock
    Size
    QTY
  • BMS-986142
    T51381643368-58-4
    BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).
    • $143
    In Stock
    Size
    QTY
  • Avitinib
    T30241557267-42-1
    Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of Ys, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.
    • $41
    In Stock
    Size
    QTY
  • Spebrutinib
    T26031202757-89-8
    Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
    • $35
    In Stock
    Size
    QTY
  • NX-2127
    T734632416131-46-7
    NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.NX-2127 potently catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) at 25 nM and 54 nM, respectively. NX-2127 is associated with the immune system, stimulating T cell activation and increasing IL-2 production in primary human T cells.
    • $109
    In Stock
    Size
    QTY
  • CHMFL-BMX-078
    T42681808288-51-8
    CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
    • $80
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BMS-935177
    T146811231889-53-4
    BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.
    • $36
    In Stock
    Size
    QTY
  • BTK-IN-27
    T798121841502-36-0
    BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM. It is suitable for the research of various conditions including cancer, lymphoma, leukemia, and immunological diseases [1].
    • Inquiry Price
    Size
    QTY
  • Rilzabrutinib
    T125421575596-29-0
    Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
    • $118
    In Stock
    Size
    QTY
  • zanubrutinib
    T75841691249-45-2
    Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).
    • $57
    In Stock
    Size
    QTY
  • G-744
    T153651346669-54-2
    G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthritis.
    • $2,870
    Backorder
    Size
    QTY
  • Fenebrutinib
    TQ02421434048-34-6
    Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
    • $36
    In Stock
    Size
    QTY
  • ARQ 531
    T143232095393-15-8
    ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.
    • $51
    In Stock
    Size
    QTY
  • PF-06250112
    T12673L1609465-89-5
    PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC (IC50s: 0.9 nM and 1.2 nM, respectively).
    • $1,970
    Backorder
    Size
    QTY
  • SB-633825
    T16853956613-01-7
    SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, 150 nM, respectively).
    • $196
    5 days
    Size
    QTY